Coreline Soft to showcase AVIEW COPD solution at GOLD International COPD Conference

This week marks Respiratory Care Week, an event designated by the American Association for Respiratory Care (AARC) to raise awareness about lung health. Throughout the week, educational events, information sharing, and awareness campaigns are taking place across the U.S., emphasizing the vital role that respiratory care plays in public health.

Amid these activities, Coreline Soft, a Korean developer of AI medical imaging software, announced on Tuesday its participation in the upcoming GOLD International COPD Conference, set to take place from Nov. 11-12 in Philadelphia, Pennsylvania.

The conference is the largest gathering focused on chronic obstructive pulmonary disease (COPD) and is hosted by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in collaboration with Temple Lung Center (TLC). At the conference, Coreline Soft will showcase its AVIEW COPD solution, an AI-powered tool for early COPD diagnosis.

COPD, the third leading cause of death globally according to the World Health Organization (WHO), is among the top five non-communicable diseases to manage worldwide. The COPD treatment market, valued at $19.8 billion in 2021, is expected to grow at a compound annual growth rate (CAGR) of 4.4 percent through 2031, according to India-based Transparency Market Research. 

In Korea, the prevalence rate of COPD stands at 10.8 percent for individuals aged 40 and over, and 27.3 percent for those aged 70 and over. However, the diagnosis rate remains low at just 2.8 percent, signaling a need for greater awareness.

AVIEW COPD utilizes AI to automate image analysis for diagnosing COPD, analyzing lung parenchyma, bronchi, air traps, and blood vessels. It also fully automates the segmentation of bronchi and lobes, addressing a long-standing challenge in COPD diagnostics.

“We look forward to engaging with key customers at the GOLD International COPD Conference to discuss how AI can lead advancements in COPD research and treatment,” said James Lee, director of Coreline Soft North America. "With lung health and respiratory diseases gaining attention, we aim to contribute to timely diagnosis and disease management."

Coreline Soft's AI-based lung nodule detection solution, AVIEW Lung Nodule CAD, was the first Korean product to receive U.S. FDA certification for AI-based lung nodule detection and the fifth globally. The company has expanded its presence through partnerships with institutions like Massachusetts General Hospital, Leibniz University Hannover, and DMC Healthcare in the U.K.